ClinicalTrials.gg

Program

MBS314 for Injection

A development code.

Its studies are mostly in Multiple Myeloma, led by Beijing Mabworks Biotech.

Furthest: phase 2, since Oct 28, 20261 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Mabworks Biotech11 open or runningphase 2since Oct 28, 2026Oct 28, 2026Dec 2027phase 2 · NCT07911748

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 28, 2026First study: phase 2 study in Multiple MyelomaFirst studyNCT07911748 · 78 planned

Ahead

  1. Dec 2027Primary completion: phase 2 study in Multiple MyelomaNCT07911748

TargetBeta

CD3E →GPRC5D →read by rule
“This is a Phase I/II, multicenter, open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of MBS314, a novel asymmetric trivalent trispecific humanized antibody targeting GPRC5D, BCMA and CD3, a…”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ramantamigJohnson & Johnsonphase 37
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
QLS4131ruleQilu Pharmaceuticalphase 33
QLS32015ruleQilu Pharmaceuticalphase 32
REGN17372ruleRegeneron Pharmaceuticalsphase 21
TQB2029Sino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07911748Multiple Myeloma2Not yet recruitingDec 202778

How it is read

Names in the registry

  • “MBS314 for Injection”, 1 entry

Codes read as this program: MBS314.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.